HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arden responds to suit

This article was originally published in The Rose Sheet

Executive Summary

Lawsuit filed by The Stephan Company against Elizabeth Arden for infringing its federally registered Interlude trademark is "entirely without merit," Elizabeth Arden states in June 22 press release responding to allegations. "In fact, the U.S. Trademark Office granted Elizabeth Arden a registration for the Provocative Interlude name and will fully assert its legal rights in this matter," Arden adds. Filed in the U.S. District Court for the Southern District of New York, Stephan's suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products (1"The Rose Sheet" June 26, 2006, In Brief)...

You may also be interested in...



Suit against Arden

The Stephan Company has filed a lawsuit against Elizabeth Arden for infringing its federally registered Interlude trademark for personal care products and fragrances, company announces June 22. Filed in the U.S. District Court for the Southern District of New York, suit seeks an injunction barring Elizabeth Arden from selling Provocative Interlude fragrance and products, which are on sale in fine department stores. Arden launched Provocative Interlude in April (1"The Rose Sheet" April 3, 2006, Marketing In Brief). Stephan notes blocking further sales of the Provocative scent will prevent consumer confusion...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel